NeuroOne Medical Technologies (NMTC)
NASDAQ:NMTC
Top Page
NeuroOne Medical Technologies
(NASDAQ:NMTC)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.71
▼(-1.94% Downside)
Action:ReiteratedDate:04/09/26
The score is primarily weighed down by persistent losses and significant negative free cash flow despite improved gross margins and low leverage. Technicals are mixed but trend weak given the stock is below major moving averages. Valuation support is limited due to negative earnings and no dividend. Earnings-call guidance and product/program progress provide some offset, but liquidity/runway concerns cap upside.
Positive Factors
Improving gross margin and product profitability
Sustained gross margin improvement to roughly 55% reflects meaningful progress on product-level economics. Higher gross margins lower the revenue threshold to breakeven, improve cash conversion per procedure, and provide durable leverage as commercial volumes expand if cost efficiencies persist.
Negative Factors
Persistent negative operating cash flow
Material and ongoing cash burn constrains strategic optionality and increases reliance on external financing. With cash runway only assured through FY2026 absent milestones, the company faces sustained dilution or partnership dependence unless product revenue scales or margins improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving gross margin and product profitability
Sustained gross margin improvement to roughly 55% reflects meaningful progress on product-level economics. Higher gross margins lower the revenue threshold to breakeven, improve cash conversion per procedure, and provide durable leverage as commercial volumes expand if cost efficiencies persist.
Read all positive factors
NeuroOne Medical Technologies (NMTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$36.50M
Dividend YieldN/A
Average Volume (3M)532.45K
Price to Earnings (P/E)―
Beta (1Y)1.50
Revenue Growth250.35%
EPS Growth83.06%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.03
Shares Outstanding50,693,016
10 Day Avg. Volume702,340
30 Day Avg. Volume532,447
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)5.04
Price to Sales (P/S)2.95
P/FCF Ratio-12.22
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue3.81
Enterprise Value/Gross Profit6.94
Enterprise Value/Ebitda-4.86
Forecast
1Y Price Target
$2.25Price Target Upside212.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.14
Revenue Forecast (FY)$11.37M
NeuroOne Medical Technologies Business Overview & Revenue Model
Company Description
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephal...
How the Company Makes Money
NeuroOne makes money primarily by selling its neurosurgical electrode products and related accessories to healthcare providers (e.g., hospitals and epilepsy/surgical centers) for use in clinical procedures. Revenue is generated through product sal...
NeuroOne Medical Technologies Earnings Call Summary
Earnings Call Date:Feb 17, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Neutral
Balanced/Neutral — The call highlighted multiple operational and clinical achievements (accelerated programs, regulatory clearance, strong early clinical outcomes, product adoption, and meaningful fiscal 2026 revenue guidance of at least $10.5M). However, these positives are offset by near-term financial headwinds including a year-over-year revenue decline driven by the absence of prior license revenue, a drop in gross margin, a swing to a net loss, and a substantial reduction in cash on hand with funding only assured through fiscal 2026 unless milestones are met. The company shows promising commercial and development momentum but faces tangible liquidity and margin pressures that moderate the overall outlook.Positive Updates
Fiscal 2026 Revenue Guidance
Company projects fiscal 2026 sales of at least $10.5M, representing a minimum 17% increase versus fiscal 2025.
Negative Updates
Year-over-Year Product Revenue Decline
Product revenue declined to $2.9M in Q1 FY2026 from $3.3M in Q1 FY2025, a decrease of approximately 12.1% year-over-year (prior year included Zimmer’s initial stocking order).
Read all updates
Q1-2026 Updates
Positive
Negative
Fiscal 2026 Revenue Guidance
Company projects fiscal 2026 sales of at least $10.5M, representing a minimum 17% increase versus fiscal 2025.
Read all positive updates
Company Guidance
Management reiterated FY2026 revenue guidance of at least $10,500,000 (a minimum 17% increase vs. FY2025) and said the company is funded through FY2026, noting cash and cash equivalents of $3.6M as of 12/31/2025 (down from $6.6M on 9/30/2025), working capital of $6.8M (vs. $7.9M) and no debt as of 12/30/2025. Q1 metrics included product revenue of $2.9M (vs. $3.3M YoY, up 5.5% sequentially from $2.7M), no license revenue (vs. $3.0M prior), product gross profit of $1.6M (54.2% of revenue; $1.9M/58.9% prior; up 2.6% sequentially from $1.5M), total operating expenses of $3.3M (R&D $1.4M; SG&A $1.9M, down 7.7% YoY) and a net loss of $1.4M, or $0.03 per share (vs. net income $1.8M, $0.06 per share prior). Management expects SG&A to be roughly flat for the balance of the year while R&D may fluctuate, plans to have drug‑delivery devices available for investigational/animal use in Q3 FY2026 (about six months earlier than previously expected), aims to enroll the first registry patient by the end of Q3, and to complete the limited trigeminal launch in 2026.NeuroOne Medical Technologies Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.72M | 12.10M | 3.45M | 1.95M | 171.17K | 178.15K |
| Gross Profit | 4.78M | 8.14M | 1.08M | 456.52K | -70.79K | -97.75K |
| EBITDA | -6.83M | -3.01M | -11.84M | -11.76M | -9.91M | -9.80M |
| Net Income | -6.83M | -3.61M | -12.32M | -11.86M | -10.00M | -9.95M |
Balance Sheet | ||||||
| Total Assets | 8.58M | 10.79M | 5.37M | 8.10M | 12.82M | 7.94M |
| Cash, Cash Equivalents and Short-Term Investments | 3.56M | 6.57M | 1.46M | 5.32M | 11.14M | 6.90M |
| Total Debt | 237.38K | 266.81K | 260.16K | 184.40K | 202.90K | 315.67K |
| Total Liabilities | 2.18M | 3.71M | 4.55M | 1.85M | 3.22M | 1.38M |
| Stockholders Equity | 6.40M | 7.07M | 822.01K | 6.25M | 9.60M | 6.55M |
Cash Flow | ||||||
| Free Cash Flow | -6.26M | -2.92M | -11.13M | -13.27M | -7.79M | -8.67M |
| Operating Cash Flow | -6.16M | -2.84M | -11.01M | -12.89M | -7.52M | -8.60M |
| Investing Cash Flow | -98.08K | -81.74K | -120.20K | 2.65M | -3.24M | -67.08K |
| Financing Cash Flow | 8.69M | 8.33M | 7.27M | 7.40M | 12.02M | 11.53M |
NeuroOne Medical Technologies Technical Analysis
Negative
0.72
Price Trends
0.77
Negative
0.76
Negative
0.79
Negative
Market Momentum
<0.01
Negative
42.84
Neutral
59.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMTC, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.77, below the 50-day MA of 0.77, and below the 200-day MA of 0.79, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 42.84 is Neutral, neither overbought nor oversold. The STOCH value of 59.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NMTC.
NeuroOne Medical Technologies Risk Analysis
NeuroOne Medical Technologies disclosed 51 risk factors in its most recent earnings report. NeuroOne Medical Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeuroOne Medical Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $72.76M | -5.13 | -15.11% | ― | -13.79% | -132.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $50.20M | -2.73 | -2072.11% | ― | 27.90% | 1.62% | |
46 Neutral | $36.50M | -6.63 | -91.34% | ― | 250.35% | 83.06% | |
41 Neutral | $18.56M | -2.02 | -279.06% | ― | ― | ― | |
39 Underperform | $5.56M | -0.35 | -247.60% | ― | ― | 15.03% |
* Healthcare Sector Average
NMTC
NeuroOne Medical Technologies
0.72
0.29
67.44%
SRTS
Sensus Healthcare
4.42
-0.16
-3.49%
ECOR
Electrocore
6.21
0.69
12.50%
MODD
Modular Medical
5.10
-20.40
-80.00%
RBOT
Vicarious Surgical
0.78
-4.65
-85.64%
IINN
Inspira Technologies Oxy BHN
0.43
-0.20
-31.45%
NeuroOne Medical Technologies Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
NeuroOne Shareholders Approve Equity Plan and Reverse Split
Neutral
Apr 3, 2026
On February 25, 2026, NeuroOne Medical Technologies’ board adopted, and on April 3, 2026, shareholders approved, an amendment to the company’s 2025 Equity Incentive Plan that immediately adds 1,500,000 shares to the pool and establishe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.